Arcutis Biotherapeutics (ARQT) Earnings Date & Reports

Key Takeaways

• Arcutis Biotherapeutics (ARQT) reported third quarter 2026 product revenue of $143.9 million, up 45% year over year from $99.2 million.
• Diluted earnings per share (EPS) came in at $0.06, below the consensus estimate of roughly $0.17, while revenue modestly topped expectations near $142 million.
• The company raised full-year 2026 net product sales guidance to $535 million–$545 million, up from the prior range of $525 million–$540 million.
• ZORYVE foam 0.3% was the largest growth driver at $75.1 million, followed by cream 0.3% at $37.8 million and cream 0.15% at $27.3 million.
• Operating cash flow stayed positive at $18.9 million, with cash and marketable securities of $259.8 million at quarter end.
• For more context, explore Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
• Discover Trending AI Robots to see how AI-driven strategies are navigating current market conditions.

Earnings Context and Why It Matters

Arcutis Biotherapeutics is a commercial-stage dermatology company whose growth hinges almost entirely on the ZORYVE franchise of roflumilast-based topical treatments. Because the company only recently crossed into consistent profitability, each quarterly report is a direct test of whether prescription demand, reimbursement, and commercial spending are aligning. The third quarter of 2026 mattered because it showed whether summer seasonality would slow prescription momentum and whether heavy investment in a larger sales force and a celebrity awareness campaign would pressure the bottom line. The results confirmed robust top-line demand but also revealed the cost of aggressive commercial expansion, keeping investors focused on the balance between growth and margin.

Reported Results

Arcutis reported net product revenue of $143.9 million for the third quarter ended September 30, 2026, a 45% increase from $99.2 million a year earlier. Revenue slightly exceeded the consensus estimate of about $142 million. By product, ZORYVE topical foam 0.3% generated $75.1 million, cream 0.3% contributed $37.8 million, cream 0.15% added $27.3 million, and cream 0.05% brought in $3.7 million.

On the bottom line, the company posted net income of $8.8 million, or $0.07 basic and $0.06 diluted EPS, compared with net income of $7.4 million, or $0.06 per share, in the prior-year period. Diluted EPS of $0.06 fell short of the consensus estimate of roughly $0.17, largely reflecting sharply higher operating expenses. Selling, general and administrative (SG&A) costs rose to $99.6 million from $62.4 million, driven by marketing spend on the "Skin to Believe In" campaign and sales-force expansion, while research and development (R&D) expenses increased to $22.4 million. The company raised its full-year 2026 net product sales guidance to $535 million–$545 million.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool that helps traders and investors filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs with customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking names like ARQT across the biotech and dermatology space, the AI Screener offers a structured way to narrow the universe and spot actionable setups.

Market Reaction and Investor Sentiment

Reaction to the quarter was mixed. The top-line beat and raised full-year guidance reinforced the narrative of sustained ZORYVE demand, while the EPS miss highlighted the weight of elevated commercial spending. Investors appeared to interpret the results as evidence of healthy underlying demand offset by deliberate investment in long-term brand building. The appointment of a new chief commercial officer, effective November 4, 2026, added a leadership transition for the market to digest. Sentiment heading into the report had been broadly positive, with strong buy-side coverage and rising price targets, and the results largely preserved that confidence even as near-term profitability came in lighter than modeled.

Forward Outlook and Key Factors to Monitor

Looking ahead, the central question is whether ZORYVE can maintain its prescription trajectory while the company scales back on spending intensity over time. Management raised 2026 guidance, signaling confidence in continued momentum through the fourth quarter. Investors will watch whether gross-to-net (GTN) deductions — the discounts and rebates that reduce list prices to net revenue — keep improving toward the low-50s range, which would support margin expansion.

Regulatory catalysts also loom. A potential FDA (U.S. Food and Drug Administration) approval of ZORYVE cream 0.05% for infants as young as three months is expected in the first quarter of 2027, which could unlock a new pediatric patient population. Meanwhile, the company continues enrolling Phase 2 studies of ZORYVE foam 0.3% for hidradenitis suppurativa, with data expected in early 2027.

On the pipeline front, ARQ-234, a checkpoint agonist targeting the CD200 receptor for atopic dermatitis, has advanced into the multiple ascending dose portion of its Phase 1a/1b trial. Balancing these growth investments against profitability will be the key theme in coming quarters, and the market will be watching whether rising revenue ultimately translates into more consistent EPS beats.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations